Protein degradation targeted chimera (PROTAC) PROTAC technology began in 2001 that uses the ubiquitin-proteasome system (UPS), the intracellular “cleaner” for cleaning up denatured, mutated, or harmful proteins in cells. PROTAC, which uses […]
Read More →Preface Judging from the global drug sales trend in recent years, biological drugs have begun to become popular, while sales of small molecular drugs are declining. Innovations in research and […]
Read More →Pre-diabetes is an increasingly common public health problem that has been recognized by international organizations such as the World Health Organization, the American Diabetes Association, and the International Diabetes Federation. […]
Read More →Concert Pharma recently released the results of its phase II clinical trial evaluating the dose range of the experimental deuterated CTP-543 for patients with moderate to severe alopecia areata, an […]
Read More →Despite the popularity in the development of histone deacelytase (HDAC) inhibitors, the indications of the five already approved HDAC inhibitor drugs on the market are limited to peripheral T-cell lymphoma […]
Read More →Introduction Programmed death-ligand 1 (PD-L1) is a protein that is highly expressed on the surface of many cancer cells. As PD-L1’s receptor, PD-1 belongs to the immunoglobulin superfamily and can […]
Read More →The third-generation EGFR inhibitor, Osimertinib (Tagrisso, AZD9291), was approved by the Chinese Food and Drug Administration (NMPA) recently for first-line treatment of patients with EGFR mutation-positive advanced or metastatic non-small cell lung […]
Read More →